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Abstract
Activation of p53 function leading to cell-cycle arrest and/or apoptosis is a promising strategy for development of anti-
cancer therapeutic agents. Here, we describe a novel mechanism for stabilization of p53 protein expression via activation of
the orphan nuclear receptor, RORa. We demonstrate that treatment of cancer cells with a newly described synthetic ROR
agonist, SR1078, leads to p53 stabilization and induction of apoptosis. These data suggest that synthetic ROR agonists may
hold utility in the treatment of cancer.
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Introduction
In approximately 50% of human cancers the p53 gene is
mutated, but in the remaining half of cancers activation of p53
function is considered to be a valuable strategy for development of
anti-cancer therapeutics. p53 plays a critical role in limiting cell
proliferation and inducing apoptosis in response to cellular stress/
damage and abnormal function of p53 is associated with cancers
[1]. p53 function is tightly regulated by modulation of protein
stability. Under most conditions, p53 protein is undetectable
primarily due to interaction of p53 with the E3 ubiquitin ligase
MDM2 and succeeding proteosomal degradation. A number of
compounds that inhibit the MDM2-p53 interaction or the
subsequent steps toward proteosomal degradation are under
evaluation for their anti-cancer activity.
Epidemiological data indicates that disruption of circadian
rhythmicity is associated with development of cancer [2,3,4,5].
Based on these data, the World Health Organization has classified
shift-work associated with a disrupted circadian rhythm as a
probable carcinogen [6]. Disruption of the circadian rhythm in
rodents leads to increased tumor progresssion [7,8,9,10] and
disturbances in the expression of critical clock genes has been
noted in several breast and liver cancer cell lines [11,12,13,14].
The retinoic acid receptor-related orphan receptor a (RORa) is
a member of the nuclear receptor superfamily that plays a critical
role in regulation of the circadian clock. RORa expression
oscillates in a circadian manner and plays an important role in
modulation of expression of core clock components such as
BMAL1, CLOCK and NPAS2 [15,16,17,18,19]. RORa expres-
sion is induced in response to a variety of cellular stresses [20,21]
and is downregulated in several breast, prostate, and ovarian
cancer cell lines [21]. Additionally, RORa is expressed at very low
levels in many cancers [21] suggesting that low RORa expression
may be one mechanism underlying tumorigenesis. Based on these
reports we focused on identification of pathways where RORa
may regulate cell proliferation.
Results
A chromatin immunoprecipitation (ChIP) – microarray screen
was performed in the hepatocellular carcinoma cell line, HepG2,
to identify RORa occupancy sites within the genome as we
previously described [19]. We discovered RORa occupancy
within the proximal promoter of the SOX4 gene (Fig. 1A), which
we found particularly intriguing because of its role in the
regulation of p53 stability and function [22]. The tumor
suppressor p53 plays a critical role in limiting cell proliferation
and inducing apoptosis in response to cellular stress/damage and
abnormal function of p53 is associated with cancers [1]. SOX4
directly interacts with p53 limiting its ability to be ubiquitinated by
MDM2 and thus increases its stability [22]. In fact, induction of
SOX4 expression is required for p53 stabilization in response to
DNA damage [22]. Bioinformatic analysis of the RORa
occupancy site revealed a putative ROR response element that
was conserved between humans, mice and xenopus (Fig. 1A). We
confirmed occupancy of the SOX4 promoter by RORa using a
ChIP assay as shown in Fig. 1B. The SOX4 promoter conveyed
RORa-dependent regulation of a luciferase reporter gene in
HEK293 cells as illustrated in Fig. 1C. This regulation was
dependent on the RORE identified and shown in Fig. 1A since
mutation of the RORE sequence rendered the construct
unresponsive to RORa (Fig. 1D). Adenoviral overexpression of
RORa in HepG2 cells resulted in an increase in SOX4 mRNA
expression whereas knock-down of RORa expression reduced
SOX4 mRNA expression in the same cell line (Fig. 1D). The
limited effect on SOX4 mRNA after RORa knock-down may be
due to compensatory actions of RORc, which is known to act in
concert with RORa in HepG2 cells [23]. Based on previous
observations that altering SOX4 expression modulates p53
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stability, we hypothesized that RORa expression may correlate
with p53 protein stability [22]. Indeed, we observed that
overexpression of RORa in HepG2 cells was associated with an
increase in SOX4 expression leading to increased p53 protein levels
(Fig. 1D). Consistent with this observation, decreasing RORa
expression in these cells leads to decreased p53 protein levels
(Fig. 1E). We directly measured the stability of p53 under
conditions where RORa was overexpressed by treating cells with
cychoheximide and noted that overexpression of RORa clearly
stabilized p53 expression (Fig. 1F). Additionally, overexpression of
RORa led to increased expression of p53 target genes that play a
key role in cell cycle arrest (p21) and apoptosis (PUMA) (Fig. 2A)
[1]. Knock-down of p53 suppressed the ability of RORa
overexpression to increase the expression of these genes (Fig. 2A
lower panels). Further, analysis of HepG2 cells overexpressing
RORa revealed that the number of cells in sub-G1 increased
substantially over control cells (34% vs 8%) while cells in S and
G2/M phase were also substantially reduced consistent with
induction of apoptosis (Figs. 2B & 2C). These data are consistent
with the observed increase in p53 stability and increase in p21 and
PUMA expression noted in Fig. 2B. Furthermore, the increase in
sub-G1 cells induced by overexpression of RORa was blocked
when p53 expression was knocked down demonstrating that
RORa induction of apoptosis is p53-dependent (Fig. 2D). MCF-7
breast cancer cells show similar results when RORa is overex-
pressed; a significant increase in sub-G1 cells relative to control
cells (15.5% vs 4.5%) (Fig. 2E).
Based on or results where overexpression of RORa leads to
increased p53 protein stability, we examined the potential of a
RORa agonist we recently identified to increase p53 stability. We
recently characterized several synthetic ROR ligands including the
first synthetic, selective ROR ligand, SR1078 (Fig. 3A) [24,25,26].
SR1078 functions as an agonist by activating RORa leading to an
increase in transcription of RORa target genes [24]. Consistent
with this activity, we noted that SR1078 induced the expression of
SOX4 mRNA in HepG2 cells as well as a well-characterized
RORa target gene, REV-ERBa (Fig. 3B). We observe that
SR1078 treatment also results in an increase in p53 protein levels
(Fig. 3C) similar to the results we observed with overexpression of
RORa. SR1078 treatment also led to a significant increase in the
expression of p53 target genes p21 and PUMA (Fig. 3D). Knock-
down of p53 suppressed the ability of SR1078 to increase the
expression of these genes (Fig. 3D lower panels). Consistent with
the increase in p53 protein levels as well as the increase in the
expression of p53 target genes, we found that SR1078 treatment
led to increased apoptosis as indicated by the increase in HepG2
cells in sub-G1 (0.9% control vs. 9.4% SR1078) (Fig. 3E). The
increase in apoptosis induced by SR1078 was both RORa- and
p53-dependent since siRNA-mediated knock down of either of
these genes suppressed the ability of SR1078 to increase cells in
sub-G1 (Figs. 3F &3G).
Discussion
The tumor suppressor protein p53 plays an essential role in
regulation of key cellular processes including DNA repair, cell
cycle, and apoptosis. In approximately half of all human cancers
the p53 gene is deleted or mutated [1]. In many cancers with wild
type p53, the activity of the tumor suppressor is inhibited by
various effectors. One clear example of this is found in tumors
where MDM2 is overexpressed due to an amplification of a
chromosome segment that includes MDM2 [27]. This leads to
abnormal degradation of p53 and thus a similar phenotype to
tumors with a mutant or deleted p53 gene. Inhibition of abnormal
degradation of p53 is a logical pharmacological target and, in fact,
several small molecule inhibitors of the MDM2-p53 interaction
including nutlin-3, RITA, spirooxindoles and quilinols are being
investigated as anti-cancer agents due to their abilities to increase
cellular p53 protein levels through inhibition of MDM2-directed
proteosomal degradation of p53 [28].
Our data suggests that a small molecule synthetic RORa
agonist can increase p53 protein stability leading to increased p53
function and subsequent apoptosis. MDM2 inhibitors have been
the focus of significant efforts to develop anti-cancer agents that
function via activation of p53 activity. Here, we demonstrate that
RORa agonists may also be useful for activation of p53 activity
and thus represent a novel target for development of anti-cancer
therapeutics. Most nuclear receptors that have identified ligands
are well-characterized targets for drugs used in the clinic and the
nature of the nuclear receptor ligand binding domain typically
allows for optimization of small molecule ligands for drug
development. Thus, RORa clearly represents a unique target for
stabilization of p53 that is quite distinct from the challenging effort
to inhibit a protein-protein interaction such as the MDM2-p53
interaction. While this manuscript was under revision, Kim et al.
also described a role for p53 in regulation of p53 stability and
function [29]. Although they show also that RORa regulates p53
stability they demonstrate a distinct mechanism from that
proposed in this manuscript for increasing p53 stability involving
the enhancement of p53-HAUSP interaction [29]. Kim et al
indicate that they could not rule out additional non-HAUSP
mechanism for regulation of p53 stability by RORa [29], which is
consistent with our observation that RORa directly regulates the
expression of SOX4, a critical gene involved in MDM2-dependent
regulation of p53 stability.
Methods
Plasmids and viruses
The SOX4 promoter (21121 to +90) was amplified from
genomic DNA of HepG2 cells (ATCC, Manassas, VA) and cloned
into pTAL-Luc luciferase report vector (Clontech, CA) to make
the pTAL-SOX4 reporter construct. PGL4.73 reporter was from
Promega (Madison, WI). pTrex-RORa and pTrex-RORc were
from Phenex Pharmaceuticals AG. RORa was tagged with FLAG
and subcloned into pAd/CMV/V5-DEST vector through Gate-
wayTM technique (Invitrogen). The adenovirus with FLAG-RORa
was produced according to the manufacturer’s instructions.
Site-directed Mutagenesis
The SOX4 promoter mutant constructed by site directed
mutagenesis as previously described [25,30]. The RORE (2178 to
2165) was mutated from GGAATGAGGTCAG to GGAAT-
GAGGGGGG. The mutant primers targeting ROR binding site
are: GCTCTGTAAATTGGAATGAGGGGGATTTGGAGC-
TTCTC (forward) and GAGAAGCTCCAAATCCCCCTCA-
TTCCAATTTACAGAGC (reverse). The mutant primers were
used to amplify mutant plasmid from pTAL-SOX4 reporter using
PfuUltra HF DNA polymerase. The PCR product were treated
with Dpn I to select for mutation-containing synthesized DNA and
then transformed into XL1-Blue supercompetent cells. Positive
clones were picked up and grew overnight in LB media. The
plasmid were isolated using QIAprep Spin Miniprep Kit (Qiagen).
The mutant construct was verified by sequencing.
Cell culture and luciferase assay
HEK293 cells (ATCC) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
Stabilization of p53 by a Synthetic ROR Agonist
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serum (Invitrogen, Carlsbad, CA) at 37uC under 5% CO2. 24 h
prior to transfection, HEK293 cells were plated in 96-well plates at
a density of 156103 cells/well. Transfections were performed
using LipofectamineTM 2000 (Invitrogen). Each well was trans-
fected with 20 ng pGL4.73, 50 ng ROR and 100 ng pTAL-Luc or
mutant. Eight hours post-transfection, the cells were treated with
vehicle or ligands. Twenty-four hours post-treatment, the
luciferase activity was measured using the Dual-GloTM luciferase
assay system (Promega). The value from experimental reporter was
normalized to control reporter. The values indicated represent the
means 6 S.E. from four independently transfected wells. The
experiments were repeated at least three times.
Overexpression of RORa and siRNA Knockdown
The HepG2 cells (ATCC) were maintained in MEM supple-
mented with 10% fetal bovine serum at 37uC under 5% CO2.
HepG2 cells were plated in 6-well plate one day before infection.
The cells were infected with adenovirus for 24 hours and then
Figure 1. Identification of a RORE in the SOX4 promoter. A) Schematic representing the SOX4 gene. The single exon gene is shown in the
diagram the untranslated regions are also shown. The area where significant RORa occupancy was detected in the ChIP-microarray screen is indicated
above the gene. The putative RORE is shown below the gene structure and alignment illustrates absolute conservation between xenopus, mouse and
human sequences. The RORE is indicated by the underlined sequence. Alignment of the putative SOX4 RORE with the prototypic RORE from the
prototypic ROR target gene, BMAL1. Right Panel: Screen shot from genome browser indicating regions generating signal from the ChIP/chip study on
both SOX4 and the positive control ARNTL (BMAL1). B) Chromatin immunoprecipitation assessing the occupancy of RORa at the SOX4 promoter. IgG
was used as a negative control and RNA polII was used as a positive control. C) Cotransfection assay where a luciferase reporter under the direction of
the SOX4 promoter was transfected into HEK 293 cells along with a vector directing the expression of RORa. Inclusion of RORa results in stimulation
of luciferase expression. The second panel demonstrates that when the RORE is mutated in the SOX4 promoter, which inhibits the ability of RORa to
bind, RORa no longer has the ability to activate transcription of this reporter. WT, indicates wild type and MT, indicates mutant. Empty expression
vector was included in the control wells. D) Adenoviral overexpression of RORa in HepG2 cells results in stimulation of SOX4mRNA expression relative
to the LacZ adenovirus control. Suppression of expression of RORa using siRNA results in a reduction of SOX4 mRNA. *, indicates p,0.05. E) Western
blot illustrating that overexpression of RORa results in increased p53 protein while suppression of RORa expression results in decreased p53 protein
expression. F) Analysis of the effect of RORa overexpression on the half-life of p53. HEK293 cells overexpressing either LacZ (control) or RORa were
treated with cycloheximide for various amounts of time (0, 10, 60, 90 min) and p53 protein was assessed by western analysis and normalized to
tubulin expression. Densitometry was used to assess expression and was signal was normalized to tubulin and the normalized relative (to time 0)
expression is indicated below the blots. p53 displayed a half-life of 2266 min (mean6S.E.) in the absence of RORa and a half-life.90 min with RORa
overexpressed.
doi:10.1371/journal.pone.0034921.g001
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switched to regular growth media. Twenty-four hours later, the
cells were harvested to isolate total RNA. For knockdown assay,
the control siRNA, human RORa siRNA, and human p53 siRNA
(Thermo Scientific) were transfected with LipofectamineTM
RNAiMAX (Invitrogen) by using reverse transfection. After
24 hours, cells were harvested to perform quantitative PCR assay
or western blot.
cDNA synthesis and quantitative PCR
Total RNA extraction and cDNA synthesis were performed as
described before. The quantitative PCR was performed using ABI
Prism 7900 HT detection system (Applied Biosystems, Foster City,
CA). The primers for quantitative PCR are: human RORa, A-
AACAAGCAGCGGGAGGTGA (forward) and TGGCAAAC-
TCCACCACATAC (reverse); human SOX4, GTGGTACA-
GGGGCAGTCAGT (forward) and AACACCATCACGAT-
TCCGAT (reverse); Human P21 TTAGCAGCGGAACAAG-
GAGT (forward) and CAACTACTCCCAGCCCCATA (re-
verse); human PUMA CTGTGCTCTGCCCGTGACCG (for-
ward) and CTGGGGCGGCTTCAGCCAAA (reverse); human
BAX GAGGATGATTGCCGCCGTGG (forward) and AC-
CCGGCCCCAGTTGAAGTT (reverse); human CYPB, GCAA-
ATTCCATCGTGTAATCAAG (forward) and CGTAGATGC-
TCTTTCCTCCTG (reverse). The expression of target gene was
normalized to housekeeping gene CYPB.
Western Analysis
HepG2 cells were washed once with phosphate-buffered saline
and then incubated for 10 min at 4uC in 100 ml of TNT lysis
buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 1% Triton
X-100) and a complete miniprotease inhibitor mixture (Roche
Applied Science). Samples were then scraped and harvested into
1.5-ml microcentrifuge tubes, vortexed for 30 s, and then
centrifuged (4256g for 10 min). Protein levels in the supernatants
Figure 2. RORa regulates p53 function. A.) Overexpression of RORa in HepG2 cells results in increased expression of p53 target genes including
p21, BAX, and PUMA. In control cells where the RORa adenovirus was not included, a control LacZ adenovirus was used. *, indicates p,0.05.
Experiments shown in the lower panels were performed identical to the upper panels with the exception of inclusion of siRNA treatments as
indicated. B) Cell cycle analysis of control HepG2 cells infected with LacZ adenovirus (top) or RORa adenovirus (bottom). C) Analysis of the number of
cells in various stages of the cell cycle in control or RORa overexpressing HepG2 cells. D) Cell cycle analysis of HepG2 cells overexpression RORa
(adenovirus treatment) after treatment with either control siRNA or p53 siRNA. E) Analysis of the number of MCF-7 breast cancer cells in sub-G1
infected with control adenovirus (LacZ) or RORa adenovirus. *, indicates p,0.05.
doi:10.1371/journal.pone.0034921.g002
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were determined using a Coomassie protein assay kit (Bio-Rad),
and 20 mg of protein from each sample was separated by
SDSPAGE (BioRad - 10%) and then transferred to a polyviny-
lidene difluoride membrane (Millipore, Milford, MA) and
immunoblotted with primary antibodies: RORa (BioLegend),
TP53 (Cell Signaling) or a-tubulin (Sigma) and horseradish
peroxidase-conjugated secondary antibodies (Jackson Immunor-
esearch). Detection of the bound antibody by enhanced chemi-
luminescence was performed according to the manufacturer’s
instructions (Santa Cruz). For p53 half-life experiments, 10 mM
cyclohexamide was added to the cells for 30, 60, or 90 minutes
prior to harvesting the HepG2 cells for western analysis.
FACS analysis
HepG2 cells and MCF7 cells (ATCC) were plated in 24-well
plates the day before infection. The cells were infected with
adenovirus 24 hours later. On the day of analysis, cells were
harvested, washed, and fixed with 70% ethanolat 220uC. Fixed
samples were washed with PBS twice and resuspended in
propidium iodide staining solution for 30 min. Stained cells were
analyzed on a FACScan flow cytometer (Beckton Dickinson).
ChIP/chip screening
HepG2 cells were infected with adenovirus for 24 hours and
then switched to regular growth media for another 24 h. The cells
were harvested and sent to Genpathway for ChIP/chip assay as
previously described [31,32,33]. The RORa ChIP/chip experi-
ment has been previously described [19].
Statistical Analysis
The Student’s t test was used to test for significant differences
between groups.
Author Contributions
Conceived and designed the experiments: TB LS YW. Performed the
experiments: LS YW. Analyzed the data: TB LS YW DK. Contributed
reagents/materials/analysis tools: TB LS YW DK. Wrote the paper: TB.
Figure 3. The RORa agonist, SR1078, increases SOX4 expression and p53 function. A) Chemical structure of SR1078. B) Treatment of
HepG2 cells with SR1078 leads to an increase in SOX4 and REV-ERBa mRNA expression. C) Treatment of HepG2 cells with SR1078 leads to increased
p53 protein levels. + indicates 1 mM and ++ indicates 5 mM SR1078. D) Treatment of HepG2 cells with SR1078 leads to increased expression of p53
target genes, p21 and PUMA. Experiments shown in the lower panels were performed identical to the upper panels with the exception of inclusion of
siRNA treatments as indicated. E) Cell cycle analysis of control HepG2 cells treated with vehicle control or SR1078. Note the substantial increase in
cells in sub-G1 following SR1078 treatment, 0.9% vs 9.4% indicated on the graph. F) Cell cycle analysis of HepG2 cells treated with either control siRNA
or RORa siRNA in the presence of vehicle control or SR1078. G) Cell cycle analysis of HepG2 cells treated with either control siRNA or p53 siRNA in the
presence of vehicle control or SR1078. *, indicates p,0.05.
doi:10.1371/journal.pone.0034921.g003
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